BCL2L1 and hepatocellular carcinoma: Therefore, A-1331852 or other strategies directed to eliminate BCL-xL, such as PROTACS, should be contemplated as potential candidates for combination therapy with regorafenib in HCC treatment and probably in other cancers that exhibit BCL-xL overexpression.